Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

ts were at least 40 years old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, confirmed by radiographs, and diagnosed according to the ACR guidelines (patients must qualify as ACR global functional status I, II or III). Eligible patients were also current users of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or acetaminophen (paracetamol) for their osteoarthritis pain and these analgesics were withdrawn before treatment with study-drug. The study enrolled both hypertensive and non-hypertensive patients (50.3% of enrolled patients were hypertensive at baseline). There were no statistically significant differences among the four treatment groups for any baseline variables, including hypertension medical history.

About naproxcinod

Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United States during the first quarter of 2009.

NOTE: Within the framework of the ACR annual meeting held in Boston from November 6 to 11, 2007, NicOx had a corporate booth to introduce the Company and its technology to the scientific and medical community in the United States.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 de
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... clinical-stage pharmaceutical company focused on the development of ... will host a conference call to discuss the ... of ORMD-0801, the company,s proprietary oral insulin capsules, ... 3, 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... October 31, 2014 Investor-Edge has ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,566.14, up 0.37%, the ...
(Date:10/31/2014)... California , November 3, 2014 ... need for men with BPH to discuss "male orgasmic ... system shows ability to treat prostate symptoms while preserving ... Inc., today welcomes the publication of a paper in ... men suffering from enlarged prostate to discuss with their ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
... (NYSE: LLY ) announced Phase I data on ... (BAFF), for use in combination with bortezomib in patients with ... be presented on Sunday, June 5 at 11:30 a.m. CDT ... (Abstract #8012) at the 47th Annual Meeting of the American ...
... May 19, 2011 Perceptive Informatics , the ... PAREXEL International Corporation (NASDAQ: PRXL ), today ... webinar entitled "Critical Tasks of Site Monitors: Using a ... industry professionals across a broad range of clinical, data ...
Cached Medicine Technology:Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 2Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 3Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 4Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 2Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 3Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 4Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 5
(Date:10/31/2014)... 2014 Monica Williams-Murphy MD , ... too well the chaos that can occur for people ... vast majority of Americans who come into the emergency ... completely unprepared for the moment and so are their ... serve as a catalyst for a family to get ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Energy Textiles ... gear. The new gear is now available online, and ... the benefits of Celliant infrared-active athletic gear over compression ... that another contract has been signed for Under Armour ... for the next eight years. In light of this ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
(Date:10/31/2014)... North Shore Eye Care today announced the ... and the addition of leading ophthalmologist, William S. Kasper, ... Shore Eye Care Medical Director, Jeffrey Martin, MD. , ... Department of Ophthalmology of Winthrop-University Hospital and has maintained ... more than 30 years. He has been named to ...
(Date:10/31/2014)... 2014 In an effort to expand services ... Jamali announced he will soon offer orthodontics at his Oral ... of November. , To build upon the high degree ... York has become known for, Dr. Jamali is welcoming an ... top learning institutions as UCLA, Stanford and UCSF. He added ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3
... Nov. 14 For the sixth consecutive,year, VSP Vision ... World Class Customer Satisfaction Award from Service Quality,Measurement Group, ... in the past two years,we have added over two ... President of Customer Service Laura Costa. "We also had ...
... Through the implementation,of its best management practices (BMPs), ... protecting the environment, the ADA told Congress today., ... have had a very positive,impact," said Dr. J. ... the House Oversight and Government Reform Committee,s,domestic policy ...
... key mechanism in how bacteria communicate with each other, a ... other bacterial diseases. , The mechanism is a chemical ... known as CAI-1, and has been isolated in the lab ... the chemical also can be used to disrupt the communication ...
... Grill & Bar, other partners and donors share ... into the new National,Pediatric Brain Tumor Consortium headquarters, ... learning in,translational research for exceptional patient care, ... Hospital(R) and Chili,s Grill & Bar(R) celebrated the ...
... Nov. 14 Transcept,Pharmaceuticals, Inc. today announced that ... Officer, will present at the 19th Annual,Piper Jaffray ... New York City,on Tuesday, November 27, 2007 at ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... 50-State Disability Rights Bus Tour and Traveling Exhibit,Returns ... Senator Tom Harkin and,other members of Congress will ... back The Road To Freedom: Keeping the Promise ... cross-country bus tour,and traveling exhibit promoting the civil ...
Cached Medicine News:Health News:VSP Vision Care Recognized for World Class Customer Satisfaction 2Health News:ADA Outlines Successful Environmental Efforts 2Health News:Princeton scientists break cholera's lines of communication 2Health News:Princeton scientists break cholera's lines of communication 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 4Health News:Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedom Bus 2Health News:Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedom Bus 3
... refrigerated floor-standing centrifuge. Mobile space saver, ... choice of accessories, analog controls, large ... shutdown (JOUAN patented pendulum system), guard ... temperature limitation, rugged motor, tough steel ...
... refrigerated bench-top centrifuge. Very ... large choice of accessories, ... true sample temperature control, ... true RCF, informative display, ...
Powerful refrigerated bench-top centrifuge. Very powerful, high capacity rotors, large choice of accessories, heat labile sample protection, guard barrier, dual lid interlock, easy to use, variable c...
GP8RF is a powerful 3-liter ventilated centrifuge which is flexible, easy to use and fit on, beside or below the lab bench. Performs separations 50-100% faster than the rest, powerful, accommodating ...
Medicine Products: